Envoy Medical (COCH) Q1 2025 earnings summary

Executive summary

• Focused on developing the Acclaim CI, a fully implanted cochlear implant, with pivotal clinical trials underway and FDA approval targeted for 2027–2028.

• Secured $10 million in additional funding to advance the pivotal clinical trial for the Acclaim cochlear implant.

• Completed enrollment of 10 participants in the first stage of the pivotal clinical trial; six activated, four pending activation.

• No serious or unanticipated adverse device effects reported; modifications from earlier studies addressed prior electrical system noise issues.

• Revenue remains minimal, derived mainly from legacy Esteem FI-AMEI device replacements, with no significant new product sales expected until Acclaim CI commercialization.

Financial highlights

• Net revenues were $46,000 in Q1 2025, down 22% year-over-year due to fewer battery replacement sales and supply chain limitations.

• Net loss attributable to common stockholders was $6.2 million for Q1 2025, compared to $7.6 million in Q1 2024.

• Research and development expenses rose 16.4% to $2.7 million, reflecting increased headcount and clinical trial costs.

• General and administrative expenses decreased 13.5% to $1.8 million, mainly due to lower legal and professional fees.

• Cash and cash equivalents stood at $5.3 million as of March 31, 2025, with $25 million in related party term loans outstanding.

Outlook and guidance

• Expect continued net losses and increased expenses as clinical trials for Acclaim CI progress and commercialization efforts ramp up.

• FDA approval for Acclaim CI anticipated in late 2027 or early 2028, with significant revenue growth dependent on successful commercialization.

• Ongoing need for additional capital through equity, debt, or strategic partnerships; substantial doubt exists about ability to continue as a going concern without further funding.

• Management expresses optimism about the pivotal clinical study's progress and market potential for the fully implanted cochlear implant.

• Forward-looking statements highlight expectations for continued operational improvements, clinical trial milestones, and market acceptance.